Evaluate for Hedge Funds
Analyze pharma and biotech opportunities with a clearer view of the events, forecasts and risks that can move markets
Evaluate helps hedge fund teams assess pharma and biotech companies, assets, forecasts and market-moving events with trusted commercial intelligence, pipeline data, valuation tools and catalyst tracking.
Why hedge fund teams use Evaluate
In pharma and biotech markets, one clinical readout, regulatory decision, patent event or competitive launch can change the investment case quickly.
Hedge fund teams need to understand where the market may be overestimating or underestimating a company, whether product forecasts are realistic, which catalysts could shift sentiment, and how competitor activity could affect revenue, market share or valuation.
Evaluate brings together company, asset, forecast, pipeline and catalyst intelligence so teams can build stronger long and short theses, monitor priority names and respond faster to market-moving developments.
drugs across marketed and pipeline assets
biopharma companies across private and listed markets
event types covering clinical, regulatory, legal and commercial catalysts
Used by 98% of the top 50 pharma companies
Trusted intelligence across the pharma and biotech ecosystem
Built for investment teams, trusted across pharma and biotech.
- Forecasts to 2032 for forward-looking market sizing and investment evaluation
- Historic sales data back to 1996 for long-term performance context
- Coverage across private and listed biopharma companies, marketed products and pipeline assets
Built for key hedge fund workflows
Get in touch
Whether you are building a long or short thesis, reviewing consensus expectations, preparing for a clinical readout or monitoring competitor activity, Evaluate helps you understand the company, product and market signals behind the investment case.
Long and short idea generation
Identify pharma and biotech companies where market expectations, product performance or upcoming catalysts may create investment opportunity.
Use Evaluate to review company portfolios, pipeline assets, forecast sales, therapy area exposure, competitor activity and key market events that could support a long or short thesis.
Useful when you need to:
- Identify companies with potential upside or downside
- Review product and pipeline exposure
- Prioritize companies for deeper research
Catalyst tracking and event monitoring
Track the clinical, regulatory, legal and commercial events that can affect pharma and biotech valuations.
Use Evaluate Biomedtracker to monitor trial readouts, PDUFA dates, approvals, patent disputes, litigation, product launches, M&A activity and competitor events across companies, drugs and therapy areas.
Useful when you need to:
- Track upcoming market-moving events
- Monitor catalysts across priority names or watchlists
- Prepare for trial readouts or regulatory decisions
Asset and pipeline analysis
Understand the commercial and competitive profile of specific drugs, marketed products and pipeline assets.
Use Evaluate to assess asset ownership, development stage, indication strategy, forecast sales, competitor products and upcoming milestones.
Useful when you need to:
- Analyze a specific drug or pipeline asset
- Assess product-level revenue potential
- Understand how a single asset could affect company value
Forecast and consensus expectation analysis
Assess where consensus forecasts diverge from market reality to identify potential gaps, pressure-test assumptions and build conviction around a product, company or therapy area.
Use Evaluate to review historic sales, consensus forecasts, forecast changes, indication-level opportunity and long-term market outlook across pharma and biotech assets.
Useful when you need to:
- Compare reported sales against forecast expectations
- Identify potential upside or downside to consensus
- Support theses with product-level data
Competitive threat monitoring
Track competitor developments and market events that could affect a company’s revenue outlook, market share or valuation.
Use Evaluate to monitor pipeline entrants, clinical trial readouts, product launches, biosimilar threats, patent cliffs, loss of exclusivity events and other signals that may shape a short thesis, impact valuation or change the investment case across relevant therapy areas.
Useful when you need to:
- Monitor threats to key products
- Track new entrants in a market
- Revisit a long or short thesis as new data emerges
Valuation and scenario planning
Assess how different commercial, clinical or competitive assumptions could affect asset or company value.
Use Evaluate’s NPV tools and forecast data to model future sales, launch timing, pricing, biosimilar risk, SG&A, tax assumptions and competitive impact.
Useful when you need to:
- Test upside and downside scenarios
- Understand sensitivity to key assumptions
- Assess valuation risk around a catalyst
The data and tools behind the workflows
Evaluate gives hedge fund teams a connected view of the companies, assets, forecasts, pipelines, events and market commentary behind pharma and biotech investment decisions.
Consensus forecasts and sales data
Review historic performance, forecast expectations and future sales potential across drugs, companies, indications and therapy areas.
Company and asset coverage
Analyze publicly traded and private biopharma companies, marketed products, pipeline assets and company portfolios.
Pipeline intelligence
Review development stage, indication focus, clinical progress and competitor activity to understand future growth potential and risk.
NPV Analyzer
Model asset value using adjustable assumptions across future sales, launch timing, pricing, competitive threats and development scenarios.
Calendar of Events
Track clinical, regulatory, legal and commercial catalysts that could affect market perception, valuation or share price movement.
Alerts
Set alerts for companies, drugs, mergers, clinical trials and events so teams can monitor priority names and respond faster to new developments.
Peer Group Analyzer
Compare companies against relevant peers to support benchmarking, market mapping and investment thesis development.
News & Insights
Keep up to date with the market signals shaping pharma and biotech investment decisions through expert analysis, exclusive interviews and market commentary.
Build stronger pharma and biotech investment theses with Evaluate
See how Evaluate helps hedge fund teams analyze companies, assess product potential, track market-moving catalysts and build stronger long and short investment theses with trusted biopharma intelligence.
Frequently Asked Questions
How can Evaluate support long and short idea generation?
Evaluate helps hedge fund teams review company portfolios, product forecasts, pipeline assets, competitive dynamics and upcoming catalysts to identify where market expectations may be too high or too low.
This can support both long and short thesis development across pharma and biotech companies.
How does Evaluate help with catalyst tracking?
Evaluate tracks clinical, regulatory, legal and commercial events, including trial readouts, approvals, PDUFA dates, patent events, litigation, product launches, M&A activity and competitor milestones.
This helps teams monitor priority names, prepare for market-moving events and respond quickly as new information emerges.
Can Evaluate help assess consensus expectations?
Yes. Evaluate provides historic sales data, consensus forecasts and product-level intelligence that can help teams assess whether expectations around a company, product or therapy area look realistic.
This is useful when reviewing potential upside or downside to revenue assumptions, launch expectations or market share.
How can Evaluate support product and pipeline analysis?
Evaluate helps teams review asset ownership, development stage, indication focus, forecast sales, competitor products and upcoming milestones.
This is particularly useful when a single product, clinical asset or pipeline event could materially affect a company’s valuation.
Can Evaluate support valuation and scenario planning?
Yes. Evaluate’s forecast data and NPV tools help teams test assumptions around future sales, launch timing, pricing, biosimilar risk, competitive impact and other variables that may affect asset or company value.
This can support upside and downside analysis around key products, events or investment theses.
